<DOC>
	<DOCNO>NCT01967589</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerability , pharmacokinetics ( exposure trial drug body ) pharmacodynamics ( effect investigate drug body ) multiple dos long act GLP-1 analogue ( NNC0113-0987 ) healthy male subject .</brief_summary>
	<brief_title>Investigation Safety , Tolerability , Pharmacokinetics Pharmacodynamics Multiple Doses Long Acting GLP-1 Analogue ( NNC0113-0987 ) Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Male , consider generally healthy , base medical history , physical examination result vital sign , electrocardiogram ( ECG ) laboratory safety test perform screen visit , judge investigator Age 1864 year ( inclusive ) time sign informed consent BMI ( body mass index ) 20.029.9 kg/m^2 ( inclusive ) History , presence , cancer , diabetes clinically significant cardiovascular , respiratory , metabolic , renal , hepatic , gastrointestinal ( GI ) , endocrinological , haematological , dermatological , venereal , neurological , psychiatric disease major disorder , judge investigator Personal family history medullary thyroid carcinoma multiple endocrine neoplasia type 2 History chronic pancreatitis idiopathic acute pancreatitis Use prescription nonprescription medicinal herbal product ( except routine vitamin ) within three week precede dosing period . Occasional use paracetamol acetylsalicylic acid permit Subject previous GI surgery , except subject underwent uncomplicated surgical procedure appendectomy , hernia surgery , biopsy , well colonic gastric endoscopy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>